BOSTON SCIENTIFIC CORP
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
BSX$44.70+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows (Unaudited)
| Three Months Ended March 31, | ||
|---|---|---|
| (in millions) | 2025 | 2024 |
| Net income (loss) | $672 | $493 |
| Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities | ||
| Depreciation and amortization | 325 | 304 |
| Deferred and prepaid income taxes | 41 | 31 |
| Stock-based compensation expense | 74 | 63 |
| Net loss (gain) on investments and notes receivable | 28 | 2 |
| Contingent consideration net expense (benefit) | 5 | 17 |
| Inventory step-up amortization | 81 | — |
| Other, net | (7) | (4) |
| Increase (decrease) in operating assets and liabilities, excluding purchase accounting: | ||
| Trade accounts receivable | (107) | (114) |
| Inventories | (109) | (124) |
| Other assets | (77) | (55) |
| Accounts payable, accrued expenses and other liabilities | (385) | (450) |
| Cash provided by (used for) operating activities | 541 | 164 |
| Investing activities: | ||
| Purchases of property, plant and equipment and internal use software | (187) | (179) |
| Payments for acquisitions of businesses, net of cash acquired | (239) | (47) |
| Payments for investments and acquisitions of certain technologies | (77) | (66) |
| Other, net | 3 | 7 |
| Cash provided by (used for) investing activities | (500) | (285) |
| Financing activities: | ||
| Payment of contingent consideration previously established in purchase accounting | — | (34) |
| Payments for royalty rights | (10) | (15) |
| Payments for finance leases | (36) | (25) |
| Payments on short-term borrowings | (1,083) | (504) |
| Net increase (decrease) in commercial paper | (192) | — |
| Proceeds from long-term borrowings, net of debt issuance costs | 1,558 | 2,145 |
| Cash used to net share settle employee equity awards | (118) | (78) |
| Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans | 115 | 80 |
| Cash provided by (used for) financing activities | 233 | 1,569 |
| Effect of foreign exchange rates on cash | 39 | (7) |
| Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents | 314 | 1,441 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | 606 | 1,055 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | $919 | $2,496 |
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(SUPPLEMENTAL INFORMATION)
| Three Months Ended March 31, | ||
|---|---|---|
| (in millions) | 2025 | 2024 |
| Supplemental Information | ||
| Stock-based compensation expense | $74 | $63 |
| Non-cash impact of transferred royalty rights | (4) | (7) |
| As of March 31, | ||
|---|---|---|
| (in millions) | 2025 | 2024 |
| Reconciliation to amounts within the unaudited consolidated balance sheets: | ||
| Cash and cash equivalents | $725 | $2,329 |
| Restricted cash and restricted cash equivalents included in Other current assets | 103 | 93 |
| Restricted cash equivalents included in Other long-term assets | 91 | 74 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | $919 | $2,496 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.